Accueil>>Signaling Pathways>> Others>> Nucleic Acid Turnover/Signaling>>Trimethoprim-PEG-amine (trifluoroacetate salt)

Trimethoprim-PEG-amine (trifluoroacetate salt)

Catalog No.GC45088

Trimethoprim is an antibiotic that inhibits dihydrofolate reductase (DHFR) and shows selectivity for bacterial DHFR over mammalian DHFR (IC50s = 5 and 30,000 nM, respectively).

Products are for research use only. Not for human use. We do not sell to patients.

Trimethoprim-PEG-amine (trifluoroacetate salt) Chemical Structure

Taille Prix Stock Qté
500μg
67,00 $US
En stock
1mg
127,00 $US
En stock
5mg
535,00 $US
En stock
10mg
936,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Trimethoprim is an antibiotic that inhibits dihydrofolate reductase (DHFR) and shows selectivity for bacterial DHFR over mammalian DHFR (IC50s = 5 and 30,000 nM, respectively). Commonly used in combination with sulfamethoxazole to minimize acquired resistance, trimethoprim has long been used against urinary tract infections. Trimethoprim-PEG-amine is a conjugated form of trimethoprim linked with polyethylene glycol (PEG) amine. The addition of PEG to drugs can provide greater solubility, longer duration of exposure, and the potential to overcome resistance associated with the drug.

Avis

Review for Trimethoprim-PEG-amine (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Trimethoprim-PEG-amine (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.